{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:33:28Z","timestamp":1768876408511,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T00:00:00Z","timestamp":1379376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["currenttherapeuticres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.curtheres.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T05:46:16Z","timestamp":1381902376000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparative Bioavailability and Tolerability of Single and Multiple Doses of 2 Diclofenac Sodium Sustained-Release Tablet Formulations in Fasting, Healthy Chinese Male Volunteers"],"prefix":"10.1016","volume":"75","author":[{"given":"Xue-Jia","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2013.09.001_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/11631550-000000000-00000","article-title":"Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients","volume":"29","author":"Arnstein","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.curtheres.2013.09.001_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/postgradmedj-2011-130291","article-title":"Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management","volume":"88","author":"Shah","year":"2012","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.curtheres.2013.09.001_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3810\/psm.2013.05.2016","article-title":"Effectiveness and safety of topical versus oral nonsteroidal anti-inflammatory drugs: A comprehensive review","volume":"41","author":"Klinge","year":"2013","journal-title":"Phys Sportsmed"},{"key":"10.1016\/j.curtheres.2013.09.001_bib4","first-page":"600","article-title":"Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety","volume":"11","author":"Martin","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.curtheres.2013.09.001_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-012-1336-0","article-title":"Evaluating the effects of diclofenac sodium and etodolac on renal hemodynamics with contrast-enhanced ultrasonography: a pilot study","volume":"69","author":"Imamura","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.09.001_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5414\/CP201658","article-title":"Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 \u00d7 12.5 mg tablets","volume":"50","author":"Armogida","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.09.001_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5414\/CP201600","article-title":"Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration","volume":"50","author":"Zeitlinger","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.09.001_bib8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/aps.2012.67","article-title":"Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund\u2019s complete adjuvant-induced arthritic rats","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.curtheres.2013.09.001_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199733030-00003","article-title":"Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls","volume":"33","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.curtheres.2013.09.001_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/chrsci\/49.6.422","article-title":"HPLC method for determination of diclofenac in human plasma and its application to a pharmacokinetic study in Turkey","volume":"49","author":"Yilmaz","year":"2011","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.curtheres.2013.09.001_bib11","first-page":"301","article-title":"Comparison of bioavailability and pharmacokinetics of diclofenac sodium and diclofenac potassium in normal and alloxan-diabetic rabbits","volume":"25","author":"Ahmad","year":"2012","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.curtheres.2013.09.001_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.18433\/J3S597","article-title":"Pharmacokinetic of diclofenac in the presence and absence of glibenclamide in the rat","volume":"12","author":"Le\u00f3n-Reyes","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.curtheres.2013.09.001_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cbi.2008.10.031","article-title":"Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes","volume":"179","author":"Lauer","year":"2009","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.curtheres.2013.09.001_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2133\/dmpk.DMPK-10-RG-009","article-title":"Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions","volume":"25","author":"Zi","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.curtheres.2013.09.001_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1476-5381.2012.01982.x","article-title":"Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety","volume":"167","author":"Xie","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2013.09.001_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/FPC.0b013e328346d2bb","article-title":"Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review","volume":"21","author":"Estany-Gestal","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.curtheres.2013.09.001_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11598170-000000000-00000","article-title":"Therapeutic efficacy and tolerability of the topical treatment of inflammatory conditions of the oral cavity with a mouthwash containing diclofenac epolamine: a randomized, investigator-blind, parallel-group, controlled, phase III study","volume":"32","author":"Serafini","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.curtheres.2013.09.001_bib18","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioanalytical method validation. May 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf. Accessed March 15, 2010."},{"key":"10.1016\/j.curtheres.2013.09.001_bib19","unstructured":"State Food and Drug Administration, Center for Drug Evaluation. Guidance for Bioavailability and Bioequivalence Studies for Chemical Drug Products in Humans. March 2005. http:\/\/www.cncro.com\/fgwjDetail_28.html. Accessed March 15, 2010."},{"key":"10.1016\/j.curtheres.2013.09.001_bib20","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. March 2003. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidance ComplianceRegulatoryInformation\/Guidances\/ucm070124.pdf. Accessed March 15, 2010."},{"key":"10.1016\/j.curtheres.2013.09.001_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.curtheres.2013.09.001_bib22","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: statistical approaches to establishing bioequivalence. January 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070244.pdf. Accessed March 15, 2010."},{"key":"10.1016\/j.curtheres.2013.09.001_bib23","first-page":"562","article-title":"Functions of the DAS software for pharmacological calculation","volume":"7","author":"Chen","year":"2002","journal-title":"Chin J Clin Pharmacol Ther"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X13000246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X13000246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T04:52:27Z","timestamp":1539319947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X13000246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":23,"alternative-id":["S0011393X13000246"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2013.09.001","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Bioavailability and Tolerability of Single and Multiple Doses of 2 Diclofenac Sodium Sustained-Release Tablet Formulations in Fasting, Healthy Chinese Male Volunteers","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2013.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}